Evaluation of the Dose Proportionality of Two Dose Strengths (1.5 and 3 mg) of Extended-release Paliperidone After a Single Administration to Healthy Men.

Trial Profile

Evaluation of the Dose Proportionality of Two Dose Strengths (1.5 and 3 mg) of Extended-release Paliperidone After a Single Administration to Healthy Men.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 May 2011

At a glance

  • Drugs Paliperidone (Primary)
  • Indications Psychotic disorders
  • Focus Pharmacokinetics
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Jan 2009 Planned patient numbers amended from 60 to 58 as reported by ClinicalTrials.gov.
    • 27 Nov 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top